Patents by Inventor Yasmin A. Chandrasekher
Yasmin A. Chandrasekher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8907068Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.Type: GrantFiled: May 21, 2008Date of Patent: December 9, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavar V. Sivakumar, Margaret D. Moore
-
Patent number: 8900578Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: July 30, 2013Date of Patent: December 2, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Publication number: 20140271645Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: ApplicationFiled: April 18, 2014Publication date: September 18, 2014Applicant: ZYMOGENETICS, INC.Inventors: Penny THOMPSON, Hal BLUMBERG, Yasmin A. CHANDRASEKHER, Julia E. NOVAK
-
Patent number: 8728469Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: GrantFiled: April 11, 2013Date of Patent: May 20, 2014Assignee: ZymoGenetics, Inc.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
-
Publication number: 20140004077Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus . IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.Type: ApplicationFiled: May 29, 2013Publication date: January 2, 2014Applicant: ZymoGenetics, Inc.Inventors: Yasmin A. CHANDRASEKHER, Patricia A. MCKERNAN
-
Publication number: 20130330330Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: ApplicationFiled: July 30, 2013Publication date: December 12, 2013Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Steven D. HUGHES, Yasmin A. CHANDRASEKHER
-
Publication number: 20130315919Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: August 6, 2013Publication date: November 28, 2013Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
-
Publication number: 20130302332Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: ApplicationFiled: April 11, 2013Publication date: November 14, 2013Inventors: Penny THOMPSON, Hal BLUMBERG, Yasmin A. CHANDRASEKHER, Julia E. NOVAK
-
Patent number: 8562984Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: GrantFiled: July 18, 2011Date of Patent: October 22, 2013Assignee: ZymoGenetics, Inc.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
-
Patent number: 8536309Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: January 12, 2012Date of Patent: September 17, 2013Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Patent number: 8524227Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: March 25, 2010Date of Patent: September 3, 2013Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Patent number: 8486382Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.Type: GrantFiled: August 7, 2009Date of Patent: July 16, 2013Assignee: ZymoGenetics, Inc.Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
-
Publication number: 20120207761Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: March 22, 2012Publication date: August 16, 2012Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
-
Publication number: 20120189628Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: ApplicationFiled: March 25, 2010Publication date: July 26, 2012Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Publication number: 20120156210Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: January 12, 2012Publication date: June 21, 2012Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
-
Patent number: 8163286Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: October 16, 2009Date of Patent: April 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Publication number: 20120089076Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: ApplicationFiled: July 18, 2011Publication date: April 12, 2012Applicant: ZYMOGENETICS, INC.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
-
Patent number: 8133487Abstract: The present invention provides methods of treating psoriasis in a subject (i.e., psoriasis associated with a joint disease), by administering to the subject an effective dose of a composition comprising a soluble IL-22R/IL-20RB heterodimeric polypeptide, wherein the heterodimeric polypeptide comprises an IL-22R extracellular domain covalently linked to an IL-20RB extracellular domain.Type: GrantFiled: January 27, 2010Date of Patent: March 13, 2012Assignee: ZymoGenetics, Inc.Inventors: Yasmin A. Chandrasekher, Julia E. Novak, Donald C. Foster, Wenfeng Xu, Stephen R. Jaspers
-
Patent number: 8124088Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: April 14, 2009Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
-
Patent number: 8003104Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: GrantFiled: April 30, 2009Date of Patent: August 23, 2011Assignee: ZymoGenetics, Inc.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak